Evidence mapPaperPMID 41897394Full record

ArticleBiomolecules2026

Divergent HIV-1 Restriction Phenotypes of IFITMs Expressed in Target Cells and Incorporated into Virions.

Smita Verma, David Prikryl, Mariana Marin, Ruben M Markosyan, Andrea Cimarelli, Gregory B Melikyan

Abstract read
In one paragraph

Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Smita VermaDepartment of Pediatrics, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0002-5229-9986
David PrikrylDepartment of Pediatrics, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA 30322, USA.
Mariana MarinDepartment of Pediatrics, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA 30322, USA.
Ruben M MarkosyanDepartment of Physiology and Biophysics, Rush University, Chicago, IL 60612, USA.
Andrea CimarelliCentre International de Recherche en Infectiologie (CIRI), Université de Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Nationale Supérieure de Lyon, 69007 Lyon, France.
Gregory B MelikyanDepartment of Pediatrics, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0001-5385-3013

Funding

Inhibition of viral membrane fusion by interferon-induced proteinsR01AI190198 · EMORY UNIVERSITY · 2025 to 2025
$2.3M
Biophysics of Protein-Mediated Membrane FusionR37AI150453 · EMORY UNIVERSITY · 2025 to 2025
$655k
ANRS|MIE AO-2022-2National Institute of Allergy and Infectious Diseases AI135806National Institute of Allergy and Infectious Diseases AI150453NIAID NIH HHS R01 AI190198NIAID NIH HHS R37 AI150453
6 · The paper itself

Abstract

Interferon-induced transmembrane proteins (IFITMs) are broad-spectrum antiviral factors that restrict the entry of many enveloped viruses, including HIV-1, by modifying host membrane properties and trapping fusion at the hemifusion stage. Beyond blocking entry in target cells, IFITMs also reduce the infectivity of virions produced from IFITM-expressing cells, a phenomenon termed "negative imprinting". Conserved motifs, such as the amphipathic helix and oligomerization motifs, have been reported to be essential for IFITM-mediated protection of target cells from viral infection. Yet, the impact of IFITM incorporation on progeny virion infectivity remains poorly defined. Here, we show that IFITM3 mutants defective in target cell protection activity still markedly impair HIV-1 fusion/infection upon incorporating into virions, without affecting viral maturation or Env incorporation. Immunofluorescence studies suggest mislocalization of the IFITM3 mutants as the reason for the lack of antiviral activity in target cells. Testing the antiviral activity of chimeras between antiviral and non-antiviral IFITM orthologs failed to clearly identify a domain responsible for reduction of HIV-1 infectivity, suggesting that multiple domains may be required for negative imprinting. Interestingly, co-incorporation of non-antiviral dog IFITM1 with human IFITM3 did not interfere with IFITM3's negative imprinting activity, despite forming mixed hetero-oligomers. This finding implies a dominant, oligomerization-independent antiviral phenotype of IFITM3 in virions. Our findings suggest that IFITMs may protect target cells and negatively imprint progeny virions through distinct mechanisms, underscoring the need to further characterize the molecular basis for the reduced fusion competence of IFITM-containing HIV-1 particles.

Indexed as

HIV-1HIV InfectionsMembrane ProteinsRNA-Binding ProteinsVirionAntigens, DifferentiationDogsHEK293 CellsHumansMutationPhenotypeVirus InternalizationAntigens, DifferentiationIFITM3 protein, humanleu-13 antigenMembrane ProteinsRNA-Binding ProteinsHIV negative imprintingIFITM mutants and chimerassubcellular localizationtarget cell protectionviral fusion

Identifiers

PMID41897394
PMCPMC13023901

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.